Bedrijfsoverzicht
Pluri Inc. is a biotechnology enterprise focused on the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies designed for various industries. The company specifically develops placenta-based cell therapy product candidates intended for the treatment of inflammatory conditions, muscle injuries, and other applications within the healthcare sector. Operating within the broader Healthcare sector and the specialized Biotechnology industry, Pluri functions as a developmental-stage entity that relies on clinical progress and technological innovation rather than established commercial sales. The company's scale is defined by a market capitalization of $33.37M, annual revenue of $1.34M, and an employee count of 127 individuals. These financial figures indicate that Pluri operates as a small-cap company with limited revenue generation relative to its market valuation, suggesting a high reliance on future product approvals and clinical trial success to achieve profitability and scale operations.
Financiële gezondheid
The company reports trailing twelve-month revenue of $1.34M, a net income of $-26,138,000, and an EBITDA of $-24,435,000, revealing a significant gap between top-line revenue and bottom-line profitability. This substantial disparity between the $1.34M in revenue and the $-26.14M net loss highlights an aggressive cost structure typical of early-stage biotechnology firms where research and development expenses heavily outweigh current sales. The company generates free cash flow of $-14,348,750, which indicates a negative cash position that necessitates continuous capital raising or the utilization of existing cash reserves to fund ongoing operations and development activities. Margin analysis shows a gross margin of 40.6%, reflecting the pricing power of its cell-based products, contrasted by an operating margin of -3285.9% and a profit margin of 0.0%, both of which underscore the severe operational losses incurred during the current development phase. In terms of balance sheet strength, Pluri holds $12.48M in cash against $34.94M in debt, creating a net negative working capital environment without a disclosed debt-to-equity ratio due to N/A data. The current ratio stands at 0.43, indicating that the company's current assets are insufficient to cover its current liabilities, which points to potential short-term liquidity constraints. Return on Equity is listed as N/A, while Return on Assets is -50.6%, metrics that collectively reveal the significant dilution of shareholder value and asset efficiency typical of a company burning through capital before reaching commercial viability.
Waarderingsbeoordeling
Valuation metrics for Pluri Inc. present a complex picture due to the lack of traditional profitability measures, with a trailing P/E ratio of N/A and a forward P/E of -1.75. The negative forward P/E ratio implies that the market is pricing in a period of continued losses or that earnings are expected to remain negative in the near term, making traditional price-to-earnings analysis inapplicable for this biotechnology asset. The price-to-book ratio is reported as -2.27, a figure that technically indicates the company's market value is below its book value, a scenario often seen in loss-making biotech firms where intangible assets and future pipeline potential are not fully captured on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 24.92 and an EV/EBITDA of -2.50 suggest that investors are valuing the company primarily on its revenue potential and intellectual property rather than current earnings or book value. The stock's trading range over the past year spans from a 52-week low of $2.82 to a high of $7.13, providing a volatility window for analysis. While the exact current price is not provided in the facts, the valuation metrics suggest the market is pricing the asset at a significant premium relative to its minimal revenue base, anticipating future growth from its cell therapy pipeline. The beta value of 0.72 indicates that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market fluctuations compared to large-cap technology or financial stocks.
Growth & Income
Pluri Inc. demonstrates a revenue growth rate of 7.0% year-over-year, while earnings growth is listed as N/A due to the company's consistent net losses. The divergence between positive revenue growth and negative earnings growth is characteristic of a company in the development stage, where top-line expansion does not yet translate to profitability, implying that revenue generation is the primary focus while the path to earnings positivity remains distant. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders but instead retains all available capital to fund research and development efforts. This reinvestment strategy is typical for biotechnology firms that must allocate resources toward clinical trials and regulatory approvals to advance their product candidates toward commercialization. The overall growth and income profile of Pluri is defined by moderate revenue expansion coupled with significant cash burn and a complete absence of dividend income, positioning the asset as a speculative investment reliant on future clinical success rather than current cash flow generation.